Faculty profile

David Anderson

ResearcherMedicineDalhousie University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Dalhousie University directory, so their courses may be missing. Find their university profile.

David Anderson

Researcher

Medicine

Health Sciences

Dalhousie University

Halifax, Nova Scotia, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
2 publications in the last five years, latest in 2026.
Principal investigator on 2 research grants (2 CIHR), most recently in 2020.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

215

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Capacity Development Data Services Learning Health System Patient Oriented Research Patient Partner Double-Dummy Extended Venous Thromboembolism Prophylaxis Out Of Hospital

Latest papers

Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty
New England Journal of Medicine · 2026
Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials
The BMJ · 2022
Serial imaging after pulmonary embolism and correlation with functional limitation at 12 months: Results of the ELOPE Study.
Research and practice in thrombosis and haemostasis · 2018

All 10 publications

Latest funding

Maritime SPOR SUPPORT Unit Phase II Proposal
CIHR · 2020 · Nominated PI
$7,327,627
EPCAT III - Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban and Aspirin to Aspirin Alone Following Total Hip and Knee Arthroplasty
CIHR · 2019 · Co-investigator
$4,482,900
Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty (EPCAT II)
CIHR · 2012 · Nominated PI
$3,044,877

All 3 grants and awards

10 publications.

Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty

Shivakumar S, Matino D, Zukor D, Kahn SR, Vincent G, Mundi R, Vendittoli P-A, Refaei M, Bohm E, Tanzer M

New England Journal of Medicine2026

DOI: 10.1056/nejmoa2603649

Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials

Marcucci M, Etxeandia-Ikobaltzeta I, Yang S, Germini F, Gupta S, Agarwal A, Ventresca M, Tang S, Morgano GP, Wang M

The BMJ202248 citationsOpen Access

DOI: 10.1136/bmj-2021-066785 PMID: W4220829984

Serial imaging after pulmonary embolism and correlation with functional limitation at 12 months: Results of the ELOPE Study.

Ma KA, Kahn SR, Akaberi A, Dennie C, Rush C, Granton JT, Anderson D, Wells PS, Rodger MA, Solymoss S, Kovacs MJ, Rudski L, Shimony A, Hernandez P, Aaron SD, Pena E, Abikhzer G, Hirsch AM, ELOPE Study group

Research and practice in thrombosis and haemostasis2018

DOI: 10.1002/rth2.12123 PMID: 30349885

A multicenter prospective study of risk factors and treatment of unusual site thrombosis.

Ma K, Wells P, Guzman C, Anderson D, Blostein M, Hirsch A, Lazo-Langner A, Kovacs MJ, Rodger M, Tagalakis V, Kahn SR

Thrombosis research2016

DOI: 10.1016/j.thromres.2016.04.014 PMID: 27318246

Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia.

Janssens A, Rodeghiero F, Anderson D, Chong BH, Boda Z, Pabinger I, Červinek L, Terrell DR, Wang X, Franklin J

Annals of hematology2016

DOI: 10.1007/s00277-016-2682-2 PMID: 27130310

Inter-observer reliability of the HERDOO2 clinical decision rule.

Gauthier K, Le Gal G, Shivakumar S, Anderson D, Chagnon I, Solymoss S, Ortel T, Yeo E, Kearon C, Rodger M

Thrombosis research2016

DOI: 10.1016/j.thromres.2016.03.015 PMID: 27031923

Dalteparin vs low-dose unfractionated heparin for prophylaxis against clinically evident venous thromboembolism in acute traumatic spinal cord injury: a retrospective cohort study.

Worley S, Short C, Pike J, Anderson D, Douglas JA, Thompson K

The journal of spinal cord medicine2008

DOI: 10.1080/10790268.2008.11760740 PMID: 18959355

Bridging the gap between primary and secondary care: use of a clinical pathway for the investigation and management of deep vein thrombosis.

Campbell S, MacDonald M, Carr B, Anderson D, MacKinley R, Cairns S

Journal of health services research & policy2008

DOI: 10.1258/jhsrp.2007.007015 PMID: 18325163

The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty.

Skedgel C, Goeree R, Pleasance S, Thompson K, O'brien B, Anderson D

The Journal of bone and joint surgery. American volume2007Senior author

DOI: 10.2106/jbjs.f.00092 PMID: 17403806

Guidelines on the Use of Intravenous Immune Globulin for Hematologic Conditions

Anderson D, Ali K, Blanchette V, Brouwers M, Couban S, Radmoor P, Huebsch L, Hume H, McLeod A, Meyer R

Transfusion Medicine Reviews2007167 citationsFirst author

DOI: 10.1016/j.tmrv.2007.01.001

Something wrong or missing on this profile? Suggest a correction

David Anderson

Research

Latest papers

Latest funding

Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty

Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials

Serial imaging after pulmonary embolism and correlation with functional limitation at 12&#xa0;months: Results of the ELOPE Study.

A multicenter prospective study of risk factors and treatment of unusual site thrombosis.

Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia.

Inter-observer reliability of the HERDOO2 clinical decision rule.

Dalteparin vs low-dose unfractionated heparin for prophylaxis against clinically evident venous thromboembolism in acute traumatic spinal cord injury: a retrospective cohort study.

Bridging the gap between primary and secondary care: use of a clinical pathway for the investigation and management of deep vein thrombosis.

The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty.

Guidelines on the Use of Intravenous Immune Globulin for Hematologic Conditions

Maritime SPOR SUPPORT Unit Phase II Proposal

EPCAT III - Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban and Aspirin to Aspirin Alone Following Total Hip and Knee Arthroplasty

Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty (EPCAT II)

Frequent collaborators

Marc Rodger

Sudeep Shivakumar

Kara Thompson

Gad Abikhzer

Eric Bohm

Samuel Campbell

Raman Mundi

Karine Gauthier

Vicky Tagalakis

Alejandro Lazo-Langner

Michael Tanzer

Pantelis Andreou

Kari Tikkinen

Philip Devereaux

Maura Marcucci

Gian Paolo Morgano

Gordon Guyatt

Holger Schunemann

Davide Matino

Philippe Violette

Rick Ikesaka

Peter Lawrence Gross

Ralph Meyer

Federico Germini

Arnav Agarwal

Serial imaging after pulmonary embolism and correlation with functional limitation at 12 months: Results of the ELOPE Study.